Skip to content

Oxytocin and Sleeve Gastrectomy

Oxytocin Serum Variation Following Laparoscopic Sleeve Gastrectomy in Morbidly Obese Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05307133
Acronym
BARIA
Enrollment
20
Registered
2022-04-01
Start date
2022-11-24
Completion date
2025-03-04
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Morbid

Brief summary

Morbid obesity has become a common condition and there is no effective drug that is able to induce a sustained weight loss. Currently bariatric surgery remains the only effective means that is able to lead to long term sustained weight loss. Oxytocin is a hormone secreted by the hypophysis that regulates negatively the adipogenesis and positively the osteogenesis. Oxytocin also regulates appetite and its role in weight loss in humans has not been investigated so far. The aim of the present study is to elucidate whether plasma levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.

Interventions

OTHERSleeve Gastreextomy

The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Women aged 18-65, pre-menopausal, * able to read and understand the written informed consent, * with a BMI \> 40 or 35 * with at least one obesity linked comorbidity among blood hypertension, * type 2 diabetes, * sleep apnea syndrome, * invalidating arthritis, * indication for sleeve gastrectomy * accepted by the multidisciplinary committee and the CPAM (local health care system agency), * affiliation to the Fre,nch health care system, * signature of the informed consent.

Exclusion criteria

* Post-menopausal women, * any other bariatric procedure that sleeve gastrectomy, history of any other bariatric procedure, * pregnancy, * age less than 18 years under, under guardianship * Patients undergoing any other procedure that the planned sleeve gastrectomy or undergoing a second bariatric procedure for a complications during the 6 months follow-up.

Design outcomes

Primary

MeasureTime frameDescription
plasma leves of oxytocin6 monthsCorrelation between plasma leves of oxytocin (pcgr/ml) and weight loss (BMI Kg/m2) 6 months after sleeve gastrectomy

Secondary

MeasureTime frameDescription
sleeve gastrectomy6 monthsCorrelation between weight 6 months after sleeve gastrectomy and fibrosis within adipose tissue

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026